ZS Pharma Submits New Drug Application to U.S. Food and Drug Administration for ZS-9 for the Treatment of Hyperkalemia

Redwood City, Calif. – May 26, 2015ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for ZS-9 (sodium zirconium cyclosilicate). The NDA requests FDA approval of ZS-9 for the treatment of hyperkalemia.

Read More

Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere’s Disease

  • Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period, p = 0.067
  • Achieved statistical significance on multiple prospectively defined secondary endpoints
  • Company believes data provide a strong basis to move forward into two parallel Phase 3 trials
  • Management will conduct a webcast and conference call to discuss the results at 4:30 p.m. EDT today

SAN DIEGO, May 21, 2015 (GLOBE NEWSWIRE)Otonomy, Inc. (Nasdaq:OTIC), a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced topline results from its Phase 2b trial evaluating OTO-104 in patients with unilateral Ménière’s disease.

Read More

Otonomy Reports First Quarter 2015 Financial Results and Provides Corporate Update

SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today reported financial results for the quarter ended March 31, 2015 and provided an update on its corporate activities and product pipeline.

Read More

ZS Pharma Reports First Quarter 2015 Financial Results and Provides ZS-9 Program Update

ZS Pharma Reports First Quarter 2015 Financial Results and Provides ZS-9 Program Update

 

Redwood City, Calif. – May 11, 2015 – ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today provided a program update on ZS-9 (sodium zirconium cyclosilicate), the Company’s investigational treatment for hyperkalemia, and reported its financial results for the first quarter ended March 31, 2015.

Read More